A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

NCT02604199 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

58

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision to discontinue trial

Conditions

Hepatitis B

Interventions

DRUG: ARC-520 Injection
OTHER: placebo
DRUG: entecavir
DRUG: tenofovir
DRUG: antihistamine

Sponsor

Arrowhead Pharmaceuticals